ecancermedicalscience

Conference Report

Cancer Immunotherapy: from the lab to clinical applications. Potential impact on cancer centres’ organisation

9 Nov 2016
Linda Cairns, Sandrine Aspeslagh, Andrea Anichini, Jon Amund Kyte, Christian Blank, Paolo Ascierto, Nicolle Rekers, Per Thor Straten, Ahmad Awada

This report covers the Immunotherapy sessions of the 2016 Organisation of European Cancer Institutes (OECI) Oncology Days meeting, which was held on 15th–17th June 2016 in Brussels, Belgium. Immunotherapy is a potential cancer treatment that uses an individual’s immune system to fight the tumour. In recent years significant advances have been made in this field in the treatment of several advanced cancers. Cancer immunotherapies include monoclonal antibodies that are designed to attack a very specific part of the cancer cell and immune checkpoint inhibitors which are molecules that stimulate or block the inhibition of the immune system. Other cancer immunotherapies include vaccines and T cell infusions. This report will summarise some of the research that is going on in this field and will give us an update on where we are at present.

Related Articles

Mohammad Saad Salim Naviwala, Mirza Rameez Samar, Daania Shoaib, Fizza Akbar, Romana Idrees, Yasmin Abdul Rashid
Fatima Shaukat, Tayyab Siddiqui, Yumna Ahmed, Muneeba Khan, Mariam Fahim, Asna Noor, Agha Muhammad Hammad Khan, Ahmed Nadeem Abbasi
Luís Felipe Leite da Silva, Erick Figueiredo Saldanha, Lucas Diniz da Conceição, Wolney de Andrade Martins, Ronaldo Altenburg Gismondi, Erito Marques de Souza Filho, Renata D’Alpino Peixoto
Johannes Matthias Weimer, Eva Kuhn, Michael Ludwig, Goodluck Lincoln Malle, Godfrid Kapipi, Valentin Sebastian Schäfer, Adnan Sadiq, Oliver Henke
Isabel Saffie-Vega, Sergio Muñoz-Navarro, Macarena Manríquez-Mimica, Jorge Sapunar-Zenteno